{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:41Z","timestamp":1740138521075,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Behav Health Serv Res"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s11414-023-09853-4","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T16:04:56Z","timestamp":1693325096000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Cost Model for a Low-Threshold Clinic Treating Opioid Use Disorder"],"prefix":"10.1007","volume":"51","author":[{"given":"Sarah E.","family":"Wakeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Shehab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-5583","authenticated-orcid":false,"given":"Robert S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"9853_CR1","unstructured":"Ahmad FB, Cisewski JA, Rossen LM. Provisional Drug Overdose Death Counts. Hyattsville, MD: National Center for Health Statistics. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 23 November, 2021."},{"issue":"8","key":"9853_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","volume":"171","author":"SE Hadland","year":"2017","unstructured":"Hadland SE, Wharam JF, Schuster MA, et al. Trends in receipt of buprenorphine and naltrexone for Opioid Use Disorder among adolescents and young adults, 2001-2014. JAMA Pediatrics 2017;171(8):747-755. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.0745.","journal-title":"JAMA Pediatrics"},{"issue":"3","key":"9853_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart G. Maintenance medication for opiate addiction: the foundation of recovery. Journal of Addictive Diseases 2012;31(3):207-25. https:\/\/doi.org\/10.1080\/10550887.2012.694598","journal-title":"Journal of Addictive Diseases"},{"key":"9853_CR4","doi-asserted-by":"publisher","DOI":"10.17226\/25310","volume-title":"Medications for Opioid Use Disorder Save Lives","year":"2019","unstructured":"Leshnner AI, Mancher M (Eds.). Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press, 2019. https:\/\/doi.org\/10.17226\/25310."},{"key":"9853_CR5","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357: j1550. https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"BMJ"},{"issue":"20","key":"9853_CR6","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1001\/jama.2020.4104","volume":"323","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE. Diagnosis and treatment of Opioid Use Disorder in 2020. JAMA 2020; 323(20):2082-2083. https:\/\/doi.org\/10.1001\/jama.2020.4104.","journal-title":"JAMA"},{"issue":"3","key":"9853_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2012.08.002","volume":"24","author":"M Edland-Gryt","year":"2013","unstructured":"Edland-Gryt M, Skatvedt AH. Thresholds in a low-threshold setting: an empirical study of barriers in a centre for people with drug problems and mental health disorders. International Journal of Drug Policy 2013;24(3):257-64. https:\/\/doi.org\/10.1016\/j.drugpo.2012.08.002.","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"9853_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugpo.2013.03.005","volume":"24","author":"IM Mofizul","year":"2013","unstructured":"Mofizul IM, Topp L, Conigrave KM, et al. Defining a service for people who use drugs as 'low-threshold': What should be the criteria? International Journal of Drug Policy 2013;24(3):220-2. https:\/\/doi.org\/10.1016\/j.drugpo.2013.03.005.","journal-title":"International Journal of Drug Policy"},{"issue":"9","key":"9853_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, et al. Buprenorphine treatment divide by race\/ethnicity and payment. JAMA Psychiatry 2019;76(9):979\u2013981. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"9853_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","volume":"40","author":"HB Hansen","year":"2013","unstructured":"Hansen HB, Siegel CE, Case BG, et al. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. Journal of Behavior Health Services and Research 2013;40(3):367-377. https:\/\/doi.org\/10.1007\/s11414-013-9341-3.","journal-title":"Journal of Behavior Health Services and Research"},{"key":"9853_CR11","doi-asserted-by":"publisher","first-page":"108710","DOI":"10.1016\/j.drugalcdep.2021.108710","volume":"223","author":"MS Schuler","year":"2021","unstructured":"Schuler MS, Dick AW, Stein BD. Growing racial\/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. Drug and Alcohol Dependence 2021; 223:108710. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108710.","journal-title":"Drug and Alcohol Dependence"},{"key":"9853_CR12","doi-asserted-by":"publisher","first-page":"107732","DOI":"10.1016\/j.drugalcdep.2019.107732","volume":"207","author":"G Lapham","year":"2020","unstructured":"Lapham G, Boudreau DM, Johnson EA, et al. Prevalence and treatment of Opioid Use Disorders among primary care patients in six health systems. Drug and Alcohol Dependence 2020;207:107732. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107732.","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"9853_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.37765\/ajmc.2020.43747","volume":"26","author":"D Polsky","year":"2020","unstructured":"Polsky D, Sen A, Arsenault A. Innovative payment to scale up access to medications for Opioid Use Disorder. American Journal of Managed Care 2020;26(7):286-287. https:\/\/doi.org\/10.37765\/ajmc.2020.43747.","journal-title":"American Journal of Managed Care"},{"issue":"5","key":"9853_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14328","volume":"6","author":"EA Taylor","year":"2023","unstructured":"Taylor EA, Cantor JH, Bradford AC, et al. Trends in methadone dispensing for Opioid Use Disorder after Medicare payment policy changes. JAMA Network Open 2023; 6(5):e2314328. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14328. Accessed 12 July, 2023.","journal-title":"JAMA Network Open"},{"issue":"4","key":"9853_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/08897077.2020.1846664","volume":"42","author":"SE Wakeman","year":"2021","unstructured":"Wakeman SE, Kane M, Powell E, et al. A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation. Substance Abuse 2021;42(4):767-774. https:\/\/doi.org\/10.1080\/08897077.2020.1846664.","journal-title":"Substance Abuse"},{"key":"9853_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","volume":"107","author":"RL Snow","year":"2019","unstructured":"Snow RL, Simon RE, Jack HE, et al. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. Journal of Substance Abuse Treatment 2019;107:1-7. https:\/\/doi.org\/10.1016\/j.jsat.2019.09.003.","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"9853_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5811\/westjem.2020.7.46079","volume":"21","author":"A Martin","year":"2020","unstructured":"Martin A, Butler K, Chavez T, et al. Beyond buprenorphine: Models of follow-up care for Opioid Use Disorder in the emergency department. The Western Journal of Emergency Medicine 2020;21(6):257-263. https:\/\/doi.org\/10.5811\/westjem.2020.7.46079.","journal-title":"The Western Journal of Emergency Medicine"},{"issue":"2","key":"9853_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/adm.0000000000000875","volume":"16","author":"S Regan","year":"2022","unstructured":"Regan S, Howard S, Powell E, et al. Emergency department-initiated buprenorphine and referral to follow-up addiction care: A program description. Journal of Addiction Medicine 2022; 16(2):216-222. https:\/\/doi.org\/10.1097\/adm.0000000000000875.","journal-title":"Journal of Addiction Medicine"},{"key":"9853_CR19","doi-asserted-by":"publisher","first-page":"108316","DOI":"10.1016\/j.jsat.2021.108316","volume":"126","author":"AM Peckham","year":"2021","unstructured":"Peckham AM, Kehoe LG, Gray JR, et al. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. Journal of Substance Abuse Treatment 2021;126:108316. https:\/\/doi.org\/10.1016\/j.jsat.2021.108316.","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"9853_CR20","first-page":"50","volume":"91","author":"ME Porter","year":"2013","unstructured":"Porter ME, Lee TH. The strategy that will fix healthcare. Harvard Business Review 2013; 91(10): 50-70. https:\/\/hbr.org\/2013\/10\/the-strategy-that-will-fix-health-care. Accessed 12 July, 2023.","journal-title":"Harvard Business Review"},{"key":"9853_CR21","doi-asserted-by":"publisher","unstructured":"Porter ME, Lee TH. Integrated Practice Units: A playbook for health care leaders. NEJM Catalyst Innovations in Care Delivery 2021;2(1). https:\/\/doi.org\/10.1056\/CAT.20.0237.","DOI":"10.1056\/CAT.20.0237"},{"issue":"9","key":"9853_CR22","first-page":"47","volume":"89","author":"RS Kaplan","year":"2011","unstructured":"Kaplan RS, Porter ME. How to solve the cost crisis in health care. Harvard Business Review 2011;89(9):47-64. https:\/\/hbr.org\/2011\/09\/how-to-solve-the-cost-crisis-in-health-care. Accessed 12 July, 2023.","journal-title":"Harvard Business Review"}],"container-title":["The Journal of Behavioral Health Services &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11414-023-09853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11414-023-09853-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11414-023-09853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T22:03:34Z","timestamp":1731017014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11414-023-09853-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["9853"],"URL":"https:\/\/doi.org\/10.1007\/s11414-023-09853-4","relation":{},"ISSN":["1094-3412","1556-3308"],"issn-type":[{"type":"print","value":"1094-3412"},{"type":"electronic","value":"1556-3308"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"18 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"S. Wakeman previously served on a clinical advisory board for Celero Systems.L Kehoe:\u2022Indivior: advisory board, speaker bureau (non-branded)\u2022PATH CCM, consulting fees and stock options\u2022MAP Health Management Peer Recovery Support Services\u2014consulting feesRS Kaplan receives equity and cash compensation as advisor to Avant-Garde Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}